Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Wegovy® (Semaglutide 2.4 mg) Pregnancy Registry Study: A Prospective Cohort Study to Investigate Safety Outcomes of Exposure to Wegovy During Pregnancy

NCT05872022 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05872022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05872022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Wegovy® (Semaglutide 2.4 mg) Pregnancy Registry Study: A Prospective Cohort Study to Investigate Safety Outcomes of Exposure to Wegovy During Pregnancy
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Enrolling by invitation
Start date
July 5, 2023
Completion date
December 30, 2032
Enrollment
728 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight, pregnancy